The key word is "perceived" and I'm sure none of t

The key word is "perceived" and I'm sure none of them are highly experienced in the "art" of investing in OTC startups. If they were, they surely couldn't justifiably point their fickle fingers at you as it would be entirely their own fault for the wager. And let's face it, it's a wager. When a company has limited resources to begin with and gets knee capped by their own founder, ridiculously shady FDA foot dragging as well as politically dragged out Mexican regulatory delays, trade war delays causing nation-wide aluminum can shortages, COVID-19 delays, issues with a nervous landlord covering his ass (also resolved) and last but very far from least, problems obtaining the bottling equipment data required by the SEC because a third party refuses to (or can't) provide it. Amazingly, the management team continued to run the equipment balls to the walls the entire time filling huge and growing orders, as well as cutting new deals to expand revenue growth. Some of the deals have not even been officially announced. Only hints were shared with any of us, but enough to know that you (we'll) get the last laugh because this management group is hell bent on turning this company and their common shares taken as partial compensation (and purchased) into a major success. The 600k+ revenue in the 2nd quarter 2020 report is just scratching the surface.